Provider review
Hims & Hers review: pricing, pharmacy, and evidence status
Released: · Last reviewed: · By Dr. Parmis
Hims & Hers offers GLP-1 medications through telehealth. Every price, credential and pharmacy claim below is labeled by evidence status and read date.
Hims & Hers has no usable published price on file. It does not name a dispensing pharmacy. It is not scored in the November 20, 2026 re-score because its pages could not be read.
Rank and score
Hims & Hers is not scored in the November 20, 2026 re-score: hims.com was unreachable in the November 20, 2026 portfolio re-read; its page was readable on November 21 and will be scored on the next re-read. Giving it points, or zeros, for pages we could not read would misstate what it discloses. See the methodology.
FDA record: FDA warning letter 716567, dated September 9, 2025 (Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)); FDA warning letter 716825, dated September 9, 2025 (Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)). FDA's index showed no close-out letter when read on November 20, 2026.
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| semaglutide (Wegovy tablets) | brand oral, FDA-approved | month-to-month | $298/mo | not published · read 2026-07-06 | Unverified — no source on file |
| tirzepatide (Mounjaro) | brand injectable, FDA-approved | month-to-month | $2,048/mo | not published · read 2026-07-06 | Unverified — no source on file |
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
Not disclosed on the pages we could read. We could not identify the medical group or prescriber entity this company uses.
Accreditation: we have not verified any accreditation or certification claim for Hims & Hers against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.
Pharmacy & compliance
Not publicly disclosed — the fulfilling pharmacy or outsourcing facility is not named. Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.
State availability
State-by-state availability is not independently verified.
Who this suits — and who it doesn't
Hims & Hers may suit patients who want a standard-dose program and are comfortable proceeding without a named dispensing pharmacy disclosed up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.
Terms to check before you pay: cancellation and refund terms could not be read in this re-score; published support response times: not published.
Sources
- FDA warning letter 716567 (Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)) — Regulator letter, captured 2026-11-20
- FDA warning letter 716825 (Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)) — Regulator letter, captured 2026-11-20
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
- FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21
2 citation ids referenced on this page (EV-0402, EV-0404) could not be resolved in the evidence ledger and are not shown above. This is an ingestion gap, not a rendered claim.
Cite this page
GLP Ranked. "Hims & Hers review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/hims-hers/
GLP Ranked. "Hims & Hers review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/hims-hers/